1Prince of Songkla University, Thailand
2Universidad del Valle, Colombia
3UC Davis MIND Institute, United States
4 UC Davis School of Medicine, United States
BibTex Citation Data :
@article{JBTR7321, author = {Nattaporn Tassanakijpanich and Ana María Cabal-Herrera and Maria Jimena Salcedo-Arellano and Randi Hagerman}, title = {Fragile X Syndrome and Targeted Treatments}, journal = {Journal of Biomedicine and Translational Research}, volume = {6}, number = {1}, year = {2020}, keywords = {Fragile X syndrome, FMR1, targeted treatment}, abstract = { Many targeted treatment studies have been carried out in individuals with Fragile X Syndrome (FXS) guided by animal studies from the Fragile X Mental Retardation 1 ( FMR1) knock out (KO) mice and the fragile X Drosophila studies. Here we review the many medications that have been studied in patients with FXS and some of these medications are available for clinical use by wise clinicians. Other medications are not currently available by prescription because they are not approved by the FDA. No medication has received specific approval for treatment of FXS, although some have shown benefit from clinical studies. There is much to be done in the treatment of those with FXS and this report describes those pharmacological treatments that target the neurobiological mechanisms that are dysregulated by the lack of the Fragile X Protein (FMRP) in those with FXS. }, issn = {2503-2178}, pages = {23--33} doi = {10.14710/jbtr.v6i1.7321}, url = {https://ejournal2.undip.ac.id/index.php/jbtr/article/view/7321} }
Refworks Citation Data :
Many targeted treatment studies have been carried out in individuals with Fragile X Syndrome (FXS) guided by animal studies from the Fragile X Mental Retardation 1 (FMR1) knock out (KO) mice and the fragile X Drosophila studies. Here we review the many medications that have been studied in patients with FXS and some of these medications are available for clinical use by wise clinicians. Other medications are not currently available by prescription because they are not approved by the FDA. No medication has received specific approval for treatment of FXS, although some have shown benefit from clinical studies. There is much to be done in the treatment of those with FXS and this report describes those pharmacological treatments that target the neurobiological mechanisms that are dysregulated by the lack of the Fragile X Protein (FMRP) in those with FXS.
Note: This article has supplementary file(s).
Article Metrics:
Last update:
The Authors submitting a manuscript do so on the understanding that if accepted for publication, copyright of the article shall be assigned to Journal of Biomedicine and Translational Research Diponegoro University as publisher of the journal.
Copyright encompasses non-exclusive rights to reproduce and deliver the article in all form and media, including reprints, photographs, microfilms and any other similar reproductions, as well as translations.
Journal of Biomedicine and Translational Research Diponegoro University, the Editors and the Advisory International Editorial Board make every effort to ensure that no wrong or misleading data, opinions or statements be published in the journal. In any way, the contents of the articles and advertisements published in the Journal of Biomedicine and Translational Research Diponegoro University (JBTR) are sole and exclusive responsibility of their respective authors and advertisers.
The Copyright Transfer Form can be downloaded here: [Copyright Transfer Form JBTR]
The copyright form should be signed originally and send to the Editorial Office in the form of original mail, scanned document or fax : Journal of Biomedicine and Translational Research Faculty of Medicine, Diponegoro UniversityJl. Prof. Soedarto, Kampus UNDIP Tembalang, Semarang, Central Java, Indonesia 50275, Telp.: +62-24-8454714, Fax.: +62-24-8454714Email: jbtr@fk.undip.ac.id
JBTR by https://ejournal2.undip.ac.id/index.php/jbtr is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
View My Stats